This is followed by hair loss in the vertex area, which expands circumferentially. As hair thinning and loss in these two areas expands, they ultimately join. The occipital and parietal hair ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

V2 exhibits interdigitated columnar organizations for color and disparity that involved feedforward and feedback processing, while the texture selectivity is primarily driven by feedback modulations ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $503.20, representing a -1.37% change from its previous close. Amicus Therapeutics (FOLD) reported earnings 30 days ago.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

The area has been experiencing a renaissance of sorts with more and more restaurants and nightlife venues opening. Plus, accommodations here are generally more affordable than those found by the ...

With over 10 million people affected worldwide, Parkinson's disease is the fastest-growing neurological disorder. More than ...